Axsome Therapeutics Reports Strong Q1 Revenue Growth and Key Pipeline Advancements

summarizeSummary

Axsome Therapeutics reported strong Q1 2026 revenue growth of 57% year-over-year, alongside significant pipeline advancements like an NDA submission for AXS-12 and detailed commercial launch plans for AUVELITY's new indication.

check_boxKey Events

• Strong Q1 2026 Revenue Growth

  Total net product revenue reached $191.2 million, marking a 57% year-over-year increase. AUVELITY sales grew 59% to $153.2 million, and SUNOSI sales increased 34% to $33.9 million.

• NDA Submitted for AXS-12 in Narcolepsy

  The company announced the submission of a New Drug Application (NDA) to the FDA for AXS-12, an investigational treatment for cataplexy in narcolepsy, representing a significant regulatory milestone.

• AUVELITY Commercial Launch on Track for Alzheimer's Agitation

  Following the recent FDA approval, the full commercial launch of AUVELITY for agitation associated with dementia due to Alzheimer's disease is on track for June 2026, supported by a substantially complete expansion of the sales force to approximately 630 representatives.

• Expanded Pipeline and Clinical Progress

  Axsome added AXS-20 (balipodect) for schizophrenia and Tourette syndrome to its pipeline and anticipates multiple clinical trial initiations and topline results across its neuroscience portfolio in 2026 and 2027.

auto_awesomeAnalysis

Axsome Therapeutics delivered robust first-quarter 2026 financial results, highlighted by significant revenue growth across its product portfolio. The company's total net product revenue increased by 57% year-over-year, driven by strong sales of AUVELITY and SUNOSI. While the net loss widened due to increased investments in research, development, and commercialization, the company maintains sufficient cash to fund operations into cash flow positivity. This filing also details crucial pipeline progress, including the submission of an NDA for AXS-12 for narcolepsy and the addition of AXS-20 to its pipeline. The detailed commercialization plans for AUVELITY's recently approved Alzheimer's disease agitation indication, including an expanded sales force and a June 2026 launch target, are particularly important for future growth.